About Us

Tej Kohli Ventures was founded to invest in the most ground-breaking ideas and people at the cutting edge of ethical, sustainable technology and developments.

Tej Kohli Ventures is committed to fostering further innovation.

Read More

Tej Kohli

Entrepreneur and Philanthropist

Tej Kohli is a tech entrepreneur and philanthropist who believes that emerging technologies hold the key to improving the lives of millions of people across the globe, and will create a better tomorrow. Through Kohli Ventures, Mr Kohli has a global reach to support the pioneers and innovators who are breaking entirely new ground and shaping a brighter future.

Read More
Self-made billionaire Tej Kohli

Areas of Investment

The Kohli Impact Investment Initiative is a fund that aims to help tech companies with an innovative and ethical focus to develop their ideas and establish their presence.



Pursuing a humanitarian vision for the impact and potential of AI and robotics.

Continue to Read



Supporting the digital solutions that are making business more accessible and efficient than ever before.

Continue to Read



Using biological processes to create products that enhance our quality of life.

Continue to Read



Supporting a growing field of sports entertainment consisting of competitively played video games, watched by millions around the world.

Continue to Read



Investing in the study of the genomes of organisms to further our understanding of the DNA sequence, to foster advances in biotechnology, medicine, forensics, etc.

Continue to Read
Kohli Ventures investment

Related Developments

Since 2000, the number of active AI startups has increased by 14X.

In 2017, Costa Rica ran entirely on renewable energy for 300 days – beating their record of 250 days from the year before.

It is estimated that, by 2027, 10% of global GDP could be stored using blockchain technology.

In 2017, Google’s AlphaGo AI became capable of teaching itself to beat humans at the ancient, complex Chinese game Go – without the need for human input.

In 2017, a new cancer drug was developed that can target tumours by their genetic characteristics – a huge leap forward for precision medicine.